Search
Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigationalRavulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. … [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis.
Products: Ultomiris 100mg/mL Concentrate For Solution For InfusionSufentanil
go.drugbank.com/drugs/DB00708ApprovedInvestigationalThis route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural … Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.
Propylene glycol
go.drugbank.com/drugs/DB01839ApprovedInvestigationalA clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.
Mixtures: SYSTANE HA SP SOLUCIÓN OFTÁLMICA, SYSTANE ® HA GOTAS OFTALMICAS LUBRICANTESCategories: Compounds used in a research, industrial, or household settingRaloxifene
go.drugbank.com/drugs/DB00481ApprovedInvestigationalIn addition, a clinical study consisting of postmenopausal women with documented coronary heart disease or at increased risk for coronary events showed an increased risk for fatal stroke with raloxifene … women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer.
Velmanase alfa
go.drugbank.com/drugs/DB12374ApprovedInvestigationalVelmanase alfa is a recombinant human lysosomal alpha-mannosidase developed for enzyme replacement therapy to treat alpha-mannosidosis. … Patients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex sugars in the body.
Methacholine
go.drugbank.com/drugs/DB06709Approved[L31763] In patients with AHR, a lower dose of methacholine is required to induce bronchoconstriction, which forms the basis for the methacholine challenge test to diagnose AHR. … [A229603, A229618, A229643] Methacholine is a non-specific cholinergic agonist (parasympathomimetic) that acts through muscarinic receptors in the lungs to induce bronchoconstriction.
Milrinone
go.drugbank.com/drugs/DB00235ApprovedInvestigationalHeart failure is a multifactorial condition that affects roughly 1-2% of the adult population. … Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and
Categories: Compounds used in a research, industrial, or household settingProducts: MILRINONE-BAXTER CONCENTRATED SOLUTION FOR INJECTION 10MG/10MLSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigationalthe treatment of mTNBC patients who have undergone two or more prior therapies. … As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects.
Anagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: ANAGRELID AL 0.5MG HKPOlsalazine
go.drugbank.com/drugs/DB01250ApprovedOlsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). … [A257063] It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine].